First-in-class isogenic model of the human neurovascular unit offers unparalleled human relevance for studying blood-brain barrier drug transport and neuroinflammation. BOSTON -- Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announced the launch [...]

New state-of-the-art facility in Philadelphia provides integrated lab and collaboration space along with tailored guidance to help move advanced therapies from early research to clinical readiness WALTHAM, Mass. -- Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in [...]

Initiative led by researchers in Australia and Japan aims to map cancer and immune interactions to advance precision oncology across the region PLEASANTON, Calif. and SYDNEY -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, the Garvan Institute of Medical Research in Australia and the University of Tokyo in Japan, [...]

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially worth $200+ million increases Roche’s investment in Freenome with $75 million equity instrument and R&D support through innovative applications and technology collaboration – Brisbane, CA —Freenome, an early cancer detection company developing blood-based screening tests, today announced [...]

IRVINE, Calif. -- Zymo Research, a global leader in next-generation sequencing (NGS), has entered a strategic partnership with biomodal, an omics-based life sciences technology and analytics company. As part of biomodal's certified provider network, Zymo Research's NGS Services division is now authorized to deliver services using biomodal's duet multiomics solutions, enabling researchers to access comprehensive genetic [...]

ODENSE, Denmark -- Nordic Capital today announced an agreement to become the majority owner in Evosep, a leading Danish innovator of sample preparation and separation solutions for LC-MS-based proteomics. The investment, leveraging Nordic Capital's experience as a leading investor in healthcare and life science for over 30 years, will be made in close collaboration with Evosep's founders [...]

Partnership strengthens Bio-Techne's leadership in AI-enabled protein innovation NovoBody™ Duo molecules offer multi-specific binding capabilities for advanced research and diagnostics Collaboration aligns with Bio-Techne's strategic growth pillars and megatrends in precision medicine MINNEAPOLIS and SEATTLE -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced a licensing agreement with Monod [...]

Proprietary agentic AI model transforms genomic and real-world data into actionable insights across the full drug lifecycle Enables faster development of breakthrough therapies, including tumor-agnostic cancer treatments, through a 360-degree view of the precision medicine landscape Empowers scientific researchers across the life sciences and healthcare continuum to perform large-scale data analysis for the advancement of [...]

New technology captures the biological units of communication between cells at higher yield and quality, increasing their value in understanding, diagnosing, and treating SAN FRANCISCO -- Hermes Biosciences, a life science tools company developing a benchtop, hands-off system for the isolation of extracellular vesicles (EVs), today announced it raised a Seed financing round to deliver [...]

BUILT Biotechnologies, Inc., an emerging leader in DNA Manufacturing-as-a-Service, today announced expanded commercial and manufacturing capabilities and the onboarding of more than 50 new customers with large-scale DNA construction needs for genome engineering and beyond. “Researchers advancing ambitious genome engineering programs rely on high-fidelity, large-scale DNA,” said George McArthur, PhD, CEO of BUILT. “Our unrivaled [...]